HER2 Support Group Forums - View Single Post - TapImmune announces results from HER2/neu interim study on breast cancer

News · 01-10-2013, 10:20 PM

TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.

More...

01-10-2013, 10:20 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,951	TapImmune announces results from HER2/neu interim study on breast cancer TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. More...